Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Davies, Andrew; Cummin, Thomas E; Barrans, Sharon; Maishman, Tom; Mamot, Christoph; Novak, Urban; Caddy, Josh; Stanton, Louise; Kazmi-Stokes, Shamim; McMillan, Andrew; Fields, Paul; Pocock, Christopher; Collins, Graham P; Stephens, Richard; Cucco, Francesco; Clipson, Alexandra; Sha, Chulin; Tooze, Reuben; Care, Matthew A; Griffiths, Gareth; ... (2019). Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. The lancet oncology, 20(5), pp. 649-662. Elsevier 10.1016/S1470-2045(18)30935-5

[img]
Preview
Text
showPdf.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (463kB) | Preview

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Novak, Urban

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1474-5488

Publisher:

Elsevier

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

21 Jun 2019 15:50

Last Modified:

28 Oct 2019 08:23

Publisher DOI:

10.1016/S1470-2045(18)30935-5

PubMed ID:

30948276

BORIS DOI:

10.7892/boris.129931

URI:

https://boris.unibe.ch/id/eprint/129931

Actions (login required)

Edit item Edit item
Provide Feedback